Short-Term DMOG treatment rejuvenates senescent mesenchymal stem cells by enhancing mitochondrial function and mitophagy through the HIF-1α/BNIP3 pathway.

Jiaxin Wen, Lingxian Yi, Lei Chen, Jinhan Xu, Yanmin Zhang, Qiheng Cheng, Hangyu Ping, Huanyu Wang, Feng Shuang, Wei Chai, Tujun Weng

Senior Department of Orthopaedics, The Fourth Medical Centre, Chinese PLA General Hospital, Beijing, 100048, P.R. China.Senior Department of Orthopaedics, The Fourth Medical Centre, Chinese PLA General Hospital, Beijing, 100048, P.R. China. · pubmed

Paper

Abstract

Mesenchymal stem cells (MSCs) have potential for treating degenerative and immune diseases, but their clinical efficacy is limited by senescence, characterized by mitochondrial dysfunction, impaired mitophagy, and metabolic imbalance. The goal of this study was to investigate the effects of dimethyloxalylglycine (DMOG), a hypoxia-mimetic agent that stabilizes hypoxia-inducible factor 1 alpha (HIF-1α), on rejuvenating senescent MSCs by enhancing mitochondrial function, mitophagy, and metabolic reprogramming.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Short-term DMOG treatment enhances mitochondrial function and mitophagy in senescent mesenchymal stem cells. The paper addresses the rejuvenation of senescent cells, which is directly related to the underlying mechanisms of aging and potential lifespan extension.

Author of this paper? Send a correction.